Biogen Idec Inc (BIIB) 320.14 $BIIB
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:11AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:33AM CDT
Ultragenyx Pharmaceutical has seen flat earnings estimate revisions for the current quarter along with a significant rise in its share price for the past day
'Fast Money' Recap: Waiting for the Dust to Settle
at The Street - Wed Jul 09, 4:00AM CDT
The trading panel discussed the market's fall and how to hedge your positions.
Sanofi's Basal Insulin Candidate Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:40PM CDT
Sanofi's (SNY) new drug application for its basal insulin candidate, Toujeo, has been accepted for review by the FDA.
Biogen Idec Falls 2.48% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 2.48% Loss
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Jumps after Pain Drug Performs Well in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 3:45PM CDT
BioDelivery announced positive top-line results from a pivotal phase III efficacy study evaluating their pain candidate, BEMA buprenorphine.
Alexion Pharma Looks To Life Beyond Its Blockbuster
at Investor's Business Daily - Tue Jul 08, 1:42PM CDT
Like a rock band's second album, a biotech's second drug can say a lot about its long-term prospects. Alexion Pharmaceuticals (ALXN) is about to face this test. The 22-year-old firm has become a big-cap and a perennial on the IBD 50 list of top-rated...
Bristol-Myers Gains Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 10:40AM CDT
Bristol-Myers' (BMY) HCV combo drug has been cleared in Japan.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
BioDelivery Sciences International (BDSI) Rises: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 8:04AM CDT
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Oncolytics Biotech Inc. (ONCY) in Focus: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 7:44AM CDT
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.
Integra Upbeat on DuraSeal Acquisition despite Tepid Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 2:10PM CDT
On Jul 3, 2014, we initiated coverage on Integra LifeSciences Holdings Corpopration (IART).
Biotechnology for the Non Biotechnologist Seminar - 22nd-24th September, London UK
M2 - Mon Jul 07, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sfvlxp/biotechnology_for) has announced the addition of the "Biotechnology for the Non Biotechnologist" conference to their offering. The Biotechnology for the Non Biotechnologist conference takes place on 22nd, 23rd and 24th September 2014 Location: The Rembrandt Hotel, London Topics to be covered at this course: Day One - Introduction to Biotechnology - Introduction to Molecular Biology - Re-Expression of Proteins - Development of Production Organisms - Fermentation Technology and Large Scale Production Day Two - Process Optimisation and Scale-Up - Analysis of Biopharmaceuticals - Product Recovery and Purification - Formulation Design of Biopharmaceuticals - Process Economics Day Three - Patenting Biotech Inventions - Patent Workshop - Regulatory Considerations - Application of Regulatory Principles - Advances in Regulation: Biosimilars - Advances in Regulation: Advanced Therapies WHY SHOULD YOU ATTEND? - Gain an introduction to the fundamental principles of biotechnology - Improve your understanding of the key techniques used by biotechnologists - Understand the importance of meeting regulatory requirements and hear about the advances being made - Learn how to identify potential patents, and why and how they must be protected - Share knowledge and experiences with fellow attendees from across Europe WHO SHOULD ATTEND? Personnel from: - Quality Assurance - Regulatory Affairs - Legal and IP - Business Development - Sales and Marketing - Engineering - Finance - Training - Administration - Management Previously attended by: - Astrazeneca Ab - Bayer Sa - Biogen Idec Ltd - Boehringer Ingleheim - Pharmaceuticals Inc. - Eli Lilly & Co Ltd - Genzyme Europe Bv - Merck Sharp & Dohme - Novartis Pharma Sa - Pfizer Global R&D - Reckitt Benckiser - Healthcare (UK) Ltd - Shire Pharmaceuticals - Ucb Sa For more information visit http://www.researchandmarkets.com/research/sf...nology_for
BIND Therapeutics (BIND) in Focus: Stock Tumbles 10.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:44AM CDT
BIND Therapeutics stock fell over 10% last trading session, reversing its recent trend
Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec
PR Newswire - Mon Jul 07, 4:55AM CDT
On Thursday, July 03, 2014, the NASDAQ Composite ended at 4,485.93, up 0.63%, the Dow Jones Industrial Average advanced 0.54%, to finish the day at 17,068.26, and the S&P 500 closed at 1,985.44, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 721.38, up 0.41%, with the index also advancing 7.38% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), InterMune Inc. (NASDAQ: ITMN), Cytokinetics Inc. (NASDAQ: CYTK) and Biogen Idec Inc. (NASDAQ: BIIB). Free technical research on ALXN, ITMN, CYTK and BIIB can be downloaded upon signing up at:
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind
PR Newswire - Fri Jul 04, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Illumina, Inc. (NASDAQ: ILMN) and MannKind Corporation (NASDAQ: MNKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4444-100free.
Jazz Pharmaceuticals to Buy Rights to Defibrotide, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 4:10PM CDT
Jazz Pharmaceuticals (JAZZ) announced that it has entered into an agreement to acquire the rights to defibrotide from Sigma-Tau Pharmaceuticals, Inc.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:11AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:33AM CDT
Ultragenyx Pharmaceutical has seen flat earnings estimate revisions for the current quarter along with a significant rise in its share price for the past day
'Fast Money' Recap: Waiting for the Dust to Settle
at The Street - Wed Jul 09, 4:00AM CDT
The trading panel discussed the market's fall and how to hedge your positions.
Sanofi's Basal Insulin Candidate Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:40PM CDT
Sanofi's (SNY) new drug application for its basal insulin candidate, Toujeo, has been accepted for review by the FDA.
Biogen Idec Falls 2.48% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 2.48% Loss
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Jumps after Pain Drug Performs Well in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 3:45PM CDT
BioDelivery announced positive top-line results from a pivotal phase III efficacy study evaluating their pain candidate, BEMA buprenorphine.
Alexion Pharma Looks To Life Beyond Its Blockbuster
at Investor's Business Daily - Tue Jul 08, 1:42PM CDT
Like a rock band's second album, a biotech's second drug can say a lot about its long-term prospects. Alexion Pharmaceuticals (ALXN) is about to face this test. The 22-year-old firm has become a big-cap and a perennial on the IBD 50 list of top-rated...
Bristol-Myers Gains Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 10:40AM CDT
Bristol-Myers' (BMY) HCV combo drug has been cleared in Japan.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
BioDelivery Sciences International (BDSI) Rises: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 8:04AM CDT
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Oncolytics Biotech Inc. (ONCY) in Focus: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 7:44AM CDT
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.
Integra Upbeat on DuraSeal Acquisition despite Tepid Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 2:10PM CDT
On Jul 3, 2014, we initiated coverage on Integra LifeSciences Holdings Corpopration (IART).
Biotechnology for the Non Biotechnologist Seminar - 22nd-24th September, London UK
M2 - Mon Jul 07, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sfvlxp/biotechnology_for) has announced the addition of the "Biotechnology for the Non Biotechnologist" conference to their offering. The Biotechnology for the Non Biotechnologist conference takes place on 22nd, 23rd and 24th September 2014 Location: The Rembrandt Hotel, London Topics to be covered at this course: Day One - Introduction to Biotechnology - Introduction to Molecular Biology - Re-Expression of Proteins - Development of Production Organisms - Fermentation Technology and Large Scale Production Day Two - Process Optimisation and Scale-Up - Analysis of Biopharmaceuticals - Product Recovery and Purification - Formulation Design of Biopharmaceuticals - Process Economics Day Three - Patenting Biotech Inventions - Patent Workshop - Regulatory Considerations - Application of Regulatory Principles - Advances in Regulation: Biosimilars - Advances in Regulation: Advanced Therapies WHY SHOULD YOU ATTEND? - Gain an introduction to the fundamental principles of biotechnology - Improve your understanding of the key techniques used by biotechnologists - Understand the importance of meeting regulatory requirements and hear about the advances being made - Learn how to identify potential patents, and why and how they must be protected - Share knowledge and experiences with fellow attendees from across Europe WHO SHOULD ATTEND? Personnel from: - Quality Assurance - Regulatory Affairs - Legal and IP - Business Development - Sales and Marketing - Engineering - Finance - Training - Administration - Management Previously attended by: - Astrazeneca Ab - Bayer Sa - Biogen Idec Ltd - Boehringer Ingleheim - Pharmaceuticals Inc. - Eli Lilly & Co Ltd - Genzyme Europe Bv - Merck Sharp & Dohme - Novartis Pharma Sa - Pfizer Global R&D - Reckitt Benckiser - Healthcare (UK) Ltd - Shire Pharmaceuticals - Ucb Sa For more information visit http://www.researchandmarkets.com/research/sf...nology_for
BIND Therapeutics (BIND) in Focus: Stock Tumbles 10.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:44AM CDT
BIND Therapeutics stock fell over 10% last trading session, reversing its recent trend
Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec
PR Newswire - Mon Jul 07, 4:55AM CDT
On Thursday, July 03, 2014, the NASDAQ Composite ended at 4,485.93, up 0.63%, the Dow Jones Industrial Average advanced 0.54%, to finish the day at 17,068.26, and the S&P 500 closed at 1,985.44, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 721.38, up 0.41%, with the index also advancing 7.38% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), InterMune Inc. (NASDAQ: ITMN), Cytokinetics Inc. (NASDAQ: CYTK) and Biogen Idec Inc. (NASDAQ: BIIB). Free technical research on ALXN, ITMN, CYTK and BIIB can be downloaded upon signing up at:
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind
PR Newswire - Fri Jul 04, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Illumina, Inc. (NASDAQ: ILMN) and MannKind Corporation (NASDAQ: MNKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4444-100free.
Jazz Pharmaceuticals to Buy Rights to Defibrotide, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 4:10PM CDT
Jazz Pharmaceuticals (JAZZ) announced that it has entered into an agreement to acquire the rights to defibrotide from Sigma-Tau Pharmaceuticals, Inc.
